13F Holdings
中文EN

ATRA Atara Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%

Returns

ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$120.77M$128.94M$8.57M$63.57M—
R&D expense$37.45M$151.48M$224.78M$272.53M$282.00M
SG&A expense$26.25M$39.89M$50.91M$71.55M$78.80M
Operating income$35.86M-$83.44M-$276.01M-$280.51M-$340.46M
Interest expense$3.79M$4.62M$5.29M$373,000—
Pretax income$32.72M-$85.42M-$276.11M-$228.29M-$340.10M
Income tax$31,000-$12,000$15,000$12,000$46,000
Net income$32.69M-$85.40M-$276.13M-$228.30M-$340.14M
EBITDA$37.98M-$78.39M-$271.18M-$274.86M-$331.12M
EPS (basic)2.61-11.41-65.19-2.24-3.63
EPS (diluted)2.57-11.41-65.19-2.24-3.63
Weighted avg. shares (diluted)12.72M7.49M4.24M101.99M93.67M
Balance sheet
Cash & equivalents$8.48M$25.18M$25.99M$93.09M$107.48M
Short-term investments$0$17.47M$25.88M$149.88M$264.98M
Receivables$1.25M$1.48M$34.11M$40.22M$986,000
Inventory$0$10.65M$9.71M$1.59M$0
Current assets$12.21M$64.89M$101.87M$295.08M$384.62M
PP&E, net$73,000$1.29M$3.86M$6.30M$53.78M
Total assets$20.23M$109.10M$165.50M$376.42M$468.13M
Current liabilities$14.92M$134.57M$142.23M$78.92M$105.79M
Total liabilities$58.74M$206.38M$264.74M$249.78M$188.51M
Shareholders' equity-$38.50M-$97.28M$99.23M$126.64M$279.61M
Shares outstanding7.32M5.86M4.26M95.93M91.67M
Cash flow statement
Operating cash flow-$50.94M-$68.72M-$192.98M-$270.43M-$220.52M
Capital expenditure$0$246,000$1.22M$4.19M$10.58M
Free cash flow-$50.94M-$68.96M-$194.20M-$274.62M-$231.10M
Investing cash flow$18.15M$8.62M$123.87M$202.96M$22.26M
Financing cash flow$16.10M$59.28M$2.01M$53.08M$103.94M
Depreciation & amortization$2.12M$5.05M$4.83M$5.65M$9.35M
Stock-based compensation$9.75M$27.00M$45.39M$53.84M$53.87M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.